Dry powder inhaler and methods of use

Abstract

Methods for reducing the risk of a thromboembolic event, and a related drug delivery system are provided. In some embodiments, a dose of acetylsalicylic acid can be provided in powder form to a patient using a dry powder inhaler. The dose can be effective to reduce a risk of a thromboembolic event in a patient. A dry powder inhaler used for the method can have a mouthpiece, a reservoir for receiving the dose of acetylsalicylic acid, and an actuation member for making available the dose of acetylsalicylic acid for inhalation by a patient through the mouthpiece.

1 - 20 . (canceled) 
     
     
         21 . A method of treating an inflammatory condition in a patient in need thereof, the method consisting of the step of administering through oral inhalation to a patient a single dose of acetylsalicylic acid formulated as a dry powder comprising dry particles, the dose effective to reduce inflammation in the patient, by a dry powder inhaler, the dry powder inhaler having a mouthpiece and an actuation member for making available the dose of the acetylsalicylic acid for inhalation by the patient to reduce inflammation, wherein the amount of the dose administered to the patient comprises less than 81 mg of acetylsalicylic acid, and wherein the particles have a median geometric diameter ranging from 1 μm to about 5 μm. 
     
     
         22 . The method of  claim 21 , wherein the dose comprises an amount of acetylsalicylic acid selected from the group consisting of less than 80 mg, less than 75 mg, less than 70 mg, and less than 65 mg. 
     
     
         23 . The method of  claim 21 , wherein the dose comprises an amount of acetylsalicylic acid of less than 60 mg. 
     
     
         24 . The method of  claim 21 , wherein the dose comprises an amount of acetylsalicylic acid selected from the group consisting of less than 55 mg, less than 50 mg, less than 45 mg, less than 40 mg, and less than 35 mg. 
     
     
         25 . The method of  claim 21 , wherein the dose comprises an amount of acetylsalicylic acid of less than 30 mg. 
     
     
         26 . The method of  claim 21 , wherein the dose comprises an amount of acetylsalicylic acid selected from the group consisting of less than 25 mg, less than 20 mg, less than 15 mg, less than 10 mg, less than 8 mg, less than 5 mg, and less than 2 mg. 
     
     
         27 . The method of  claim 21 , wherein the dose is administered as a preliminary treatment in response to a symptom of an inflammatory condition. 
     
     
         28 . The method of  claim 21 , wherein the inflammatory condition is selected from the group consisting of cancer, chronic obstructive pulmonary disease (COPD), arthritis, and an autoimmune disorder. 
     
     
         29 . A method of treating an inflammatory condition in a patient in need thereof, the method consisting of the step of using a drug delivery system to administer through oral inhalation to a patient a single dose of acetylsalicylic acid formulated as a dry powder comprising dry particles, the dose effective to reduce inflammation in the patient, by a dry powder inhaler, wherein said drug delivery system comprises:
 the single dose of acetylsalicylic acid; and   the dry powder inhaler, wherein the dry powder inhaler comprises a mouthpiece, a reservoir for receiving the dose of the acetylsalicylic acid, and an actuation member for making available the dose of the acetylsalicylic acid for inhalation by the patient through the mouthpiece,   wherein the amount of the dose of the acetylsalicylic acid comprises less than about 81 mg of the acetylsalicylic acid.   
     
     
         30 . The method of  claim 29 , wherein the dose comprises an amount of acetylsalicylic acid selected from the group consisting of less than 80 mg, less than 75 mg, less than 70 mg, and less than 65 mg. 
     
     
         31 . The method of  claim 29 , wherein the dose comprises an amount of acetylsalicylic acid of less than 60 mg. 
     
     
         32 . The method of  claim 29 , wherein the dose comprises an amount of acetylsalicylic acid selected from the group consisting of less than 55 mg, less than 50 mg, less than 45 mg, less than 40 mg, and less than 35 mg. 
     
     
         33 . The method of  claim 29 , wherein the dose comprises an amount of acetylsalicylic acid of less than 30 mg. 
     
     
         34 . The method of  claim 29 , wherein the dose comprises an amount of acetylsalicylic acid selected from the group consisting of less than 25 mg, less than 20 mg, less than 15 mg, less than 10 mg, less than 8 mg, less than 5 mg, and less than 2 mg. 
     
     
         35 . The method of  claim 29 , wherein the inflammatory condition is selected from the group consisting of cancer, chronic obstructive pulmonary disease (COPD), arthritis, and an autoimmune disorder.